Sinil Pharmaceutical Co. Ltd (012790) — Cash Flow-to-Debt Ratio
Sinil Pharmaceutical Co. Ltd (012790) has a Cash Flow-to-Debt Ratio of 0.14x as of September 2025, meaning its operating cash flow of ₩2.62 Billion could theoretically repay 0% of its total liabilities (₩18.23 Billion) in one year. Explore how much of Sinil Pharmaceutical Co. Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sinil Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Sinil Pharmaceutical Co. Ltd across 11 annual periods. Also explore Sinil Pharmaceutical Co. Ltd asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Sinil Pharmaceutical Co. Ltd (2014–2024)
Year-by-year debt coverage analysis for Sinil Pharmaceutical Co. Ltd. For market capitalisation and broader financial context, see market value of Sinil Pharmaceutical Co. Ltd.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.17x | ₩22.69 Billion | ₩19.36 Billion | ▲ +35.9% |
| 2023 | 0.86x | ₩15.15 Billion | ₩17.56 Billion | ▲ +23.3% |
| 2022 | 0.70x | ₩13.69 Billion | ₩19.55 Billion | ▼ -1.1% |
| 2021 | 0.71x | ₩11.16 Billion | ₩15.78 Billion | ▲ +10.8% |
| 2020 | 0.64x | ₩11.06 Billion | ₩17.33 Billion | ▼ -13.9% |
| 2019 | 0.74x | ₩12.31 Billion | ₩16.59 Billion | ▼ -9.5% |
| 2018 | 0.82x | ₩9.19 Billion | ₩11.22 Billion | ▲ +9.5% |
| 2017 | 0.75x | ₩8.67 Billion | ₩11.59 Billion | ▼ -32.8% |
| 2016 | 1.11x | ₩12.09 Billion | ₩10.86 Billion | ▲ +5.8% |
| 2015 | 1.05x | ₩9.56 Billion | ₩9.09 Billion | ▲ +2.1% |
| 2014 | 1.03x | ₩9.33 Billion | ₩9.06 Billion | — |